Key Points
- Major shareholder William Scully purchased 27,000 Prothena shares at an average price of $9.47, investing $255,690 and increasing his ownership to 827,000 shares.
- PRTA shares opened at $9.60 and were down 0.9%, while the company reported a quarterly loss of $0.32 per share—better than analysts’ expected loss of $0.39—and revenue of $1.01 million.
- Institutional investors own 97.08% of Prothena, and analysts maintain a “Moderate Buy” consensus with an average price target of $24.57, despite mixed ratings.
Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) major shareholder William Scully acquired 27,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was purchased at an average price of $9.47 per share, with a total value of $255,690.00. Following the completion of the acquisition, the insider owned 827,000 shares in the company, valued at $7,831,690. The trade was a 3.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Prothena Trading Down 0.9%
PRTA stock opened at $9.60 on Friday. The stock's 50 day simple moving average is $9.07 and its 200 day simple moving average is $9.41. Prothena Corporation plc has a 12-month low of $7.73 and a 12-month high of $11.80. The stock has a market capitalization of $502.56 million, a PE ratio of -11.43, a price-to-earnings-growth ratio of 3.41 and a beta of -0.33.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%.The business had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.42 million. On average, research analysts predict that Prothena Corporation plc will post 0.08 earnings per share for the current year.
Institutional Trading of Prothena
Several large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its position in Prothena by 571.0% during the second quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 10,815 shares during the last quarter. ProShare Advisors LLC purchased a new position in Prothena in the fourth quarter worth about $100,000. PDT Partners LLC bought a new stake in shares of Prothena during the 4th quarter valued at about $108,000. Voleon Capital Management LP bought a new stake in shares of Prothena during the 2nd quarter valued at about $113,000. Finally, DRW Securities LLC purchased a new stake in shares of Prothena during the 4th quarter valued at about $114,000. Institutional investors own 97.08% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts recently commented on PRTA shares. Weiss Ratings downgraded Prothena from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 11th. Citizens Jmp raised their price target on shares of Prothena from $19.00 to $20.00 and gave the company a "market outperform" rating in a report on Friday, May 8th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Prothena in a research note on Friday, July 24th. Wall Street Zen lowered shares of Prothena from a "buy" rating to a "hold" rating in a research note on Saturday, July 25th. Finally, Citigroup reissued an "outperform" rating on shares of Prothena in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $24.57.
Read Our Latest Analysis on PRTA
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.
The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
